Bio Pharma Dive
AUGUST 26, 2020
An initial look at the vaccine's effects on the elderly shows those in their 70s had similar responses to those under 55, Moderna told a government panel.
Bio Pharma Dive
OCTOBER 25, 2021
The trial results should allow the company to ask the FDA for approval of its vaccine in younger children, just as Pfizer nears a crucial decision for its shot in 5- to 11-year olds.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
OCTOBER 13, 2021
Results suggested Pfizer's and Moderna's vaccines may serve as a more potent booster for those who initially received Johnson & Johnson's shot, although data are limited and preliminary.
Bio Pharma Dive
SEPTEMBER 20, 2021
The results position Pfizer and BioNTech to seek clearance in children as young as five years old. But the companies haven't yet shared data on a rare heart inflammation associated with their shot that's a concern for regulators.
Bio Pharma Dive
JUNE 8, 2022
The biotech claims study results could position its reformulated vaccine as a booster in the fall, though it’s unclear how well the shot can prevent sickness caused by omicron or newer strains of the variant.
Bio Pharma Dive
APRIL 11, 2023
The shot appears to generate an immune response that matches or exceeds existing vaccines, but investigators aren’t yet sure how well it can prevent illness.
Bio Pharma Dive
DECEMBER 10, 2021
Data from a small Phase 1 trial showed the biotech's vaccine spurred immune responses to four common strains, although they didn't appear significantly greater than an already available shot from Sanofi.
Expert insights. Personalized for you.
363 
Let's personalize your content